Matthew Thomas Lorincz, MD, PHD

Matthew T. Lorincz, MD, PhD, is a Clinical Professor of Neurology at the University of Michigan and Director of the Michigan NeuroSport Program. He is a nationally recognized sports neurologist with expertise in sport-related concussion, post-concussion syndrome, headache, vestibular and oculomotor dysfunction, supervised exercise-based rehabilitation, and long-term athlete brain health. Since joining the leadership of Michigan NeuroSport in 2015 and assuming the role of Director in December 2025, he has helped build the program into a nationally respected multidisciplinary center that integrates neurology, sports medicine, physical therapy, neuropsychology, athletic training, and supervised exercise services.

Dr. Lorincz also serves as Medical Director of the NeuroSport Clinic, Associate Director of the Michigan Concussion Center, Consulting Neurologist for University of Michigan Athletics, and Team Neurologist for Eastern Michigan University Athletics, a role he has held since 2014. He is also Co-Director of the University of Michigan Wilson Disease Center of Excellence. His research spans concussion recovery, clinical predictors of prolonged symptoms, supervised exercise as a biomarker of recovery, athlete brain health, and Wilson disease therapeutics and biomarkers. He has authored more than 35 peer-reviewed publications and numerous book chapters, abstracts, and invited presentations.

An accomplished educator and mentor, Dr. Lorincz has trained generations of medical students, residents, fellows, athletic trainers, and clinicians. He helped develop the NeuroSport Fellowship and has led widely accessed concussion education programs, including a Coursera course with more than 20,000 learners. His career reflects an exceptional combination of clinical excellence, research impact, educational leadership, and service to athletes and patients with complex neurologic disease.

Sports Neurology, Concussion, Long-term Consequences of Concussion and Wilson’s disease.

University of Michigan Health participates with most health insurance plans.

For a full list of publications, please see my bibliography page on the US National Library of Medicine website.

Sport Related Concussion Research
The long-term goal of my sport related concussion research is to determine optimal treatment for acute sport related concussion and to understand the long-term consequences of sport related concussion.

In Fall 2018 Dr. Lorincz was part of the leadership team that successfully applied for a University of Michigan Biosciences Initiative grant. The $5.6-million-dollar grant will support creation of the Michigan Concussion Center, a Category 1 University of Michigan Center. The Michigan NeuroSport Research program is an integral part of the Michigan Concussion Center. Dr. Lorincz is a founding member of the Michigan Concussion Center, a member of the executive committee; a four-person group the will lead the Michigan Concussion Center, and serves as the co-director the Michigan Concussion Center Clinical Core. It is anticipated that the Michigan Concussion Center will provide the critical infrastructure and foster collaborations to accelerate and advance future clinical and translational concussion research. A goal of the Michigan Concussion Center is to position the University of Michigan as a leader in concussion research and a coordinating center for pivotal trials that will positively transform the concussion care landscape.

This research has led to the following publications:

1. Reams N, Eckner J, Almeida A, Aagesen A, Giordani B, Paulson H, Lorincz M, Kutcher J. A clinical approach to the diagnosis of traumatic encephalopathy syndrome: A Review. JAMA Neurol 73(6): 743-9, 2016.
2. Swallow J, Joseph J, Willsey K, Almeida A, Lorincz M, Park P, Szerlip N, Broglio S: Online postconcussion return-to-play instructions. Journal of Neurosurgery: Pediatrics 21(1):44-48, 2018. PM29125444
3. Alsalaheen B, Bean R, Almeida A, Eckner J, Lorincz M: Characterization of cervical neuromuscular response to head-neck perturbation in active young adults. J Electromyogr Kinesiol 39: 70-76, 2018. PM29413455
4. Almeida AA, Lorincz MT, Hashikawa AN: Recent Advances in Pediatric Concussion and Mild Traumatic Brain Injury. Pediatr Clin North Am 65(6): 1151-1166, 2018. PM30446054
5. Alsalaheen B, Bean R, Almeida A, Eckner J, Lorincz M: Characterization of cervical neuromuscularresponse to head-neck perturbation in active young adults. J Electromyogr Kinesiol 39: 70-76, 2018. PM29413455
6. Popovich M, Almeida A, Freeman J, Eckner J, Alsalaheen B, Lorincz M, Sas A: Use of Supervised. Exercise During Recovery Following Sports-Related Concussion Clinical Journal of Sport Medicine. (In Press)
7. Alsalaheen B, McCloskey K, Bean R, Almeida A, Eckner J, Lorincz M: Women and men use different strategies to stabilize the head in response to impulsive loading: implications for concussion injury risk. Journal of Orthopaedic & Sports Physical Therapy. (In Press)

Wilson’s Disease Related Research
The focus of my research in Wilson’s disease has been to understand the neurologic manifestations of Wilson’s disease and to develop safe and effective treatments for Wilson’s disease. Wilson’s disease is a neurodegenerative copper metabolism disease that is fatal if unrecognized and untreated. I have been involved in clinical trials of treatment in Wilson’s disease beginning in 1999.

This research has led to the following publications:

1. Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J: Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch. Neurol. 63(4): 521-7, 2006. PM16606763
2. Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT: Treatment of Wilson's disease with tetrathiomolybdate: V. control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res 154(2): 70-7, 2009. PM19595438/PMC-
3. Lorincz MT: Neurologic Wilson's disease. Ann. N. Y. Acad. Sci. 1184: 173-87, 2010. PM20146697
4. Burke JF, Dayalu P, Nan B, Askari F, Brewer GJ, Lorincz MT: Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism Relat. Disord. 17(7): 551-6, 2011. PM21641265
5. Lorincz MT: Recognition and treatment of neurologic Wilson's disease Semin Neurol 32(5): 538-543, 2012. PM23677665
6. Lorincz MT: Neurologic Wilson's Disease. MedLink Neurology, Gilman S, editor MedLink Corporation:San Diego, Available at www.medlink.com. Annually updated 2008-2018, 2008.
7. Brewer GJ, Askari F, Lorincz MT, Carlson MD, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK,Tankanow R, Dick RB, Sitterly J: Tetrathiolmolybdate versus Trientine in the Initial Treatment of Wilson's Disease. Progress in Neurotherapeutics and Neuropsychopharmacology, Cummings, JL Editor-in-Chief Cambridge University Press, Cambridge, UK, 2008. 153-166
8. Lorincz M: Wilson’s Disease and Related Copper Disorders. Handbook of Clinical Neurology, Aminoff, Boller, Swaab Elsevier, 2018, 18, 279-292.

Current Grants

I am currently a Co-investigator with effort on a phase III trial for Wilson’s disease. A Phase 3, Randomized, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older with an Extension Phase of up to 60 Months (Wilson Therapeutics)